Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?

Mevlut Kurt Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, TurkeyCorrespondence[email protected]

Sercan Aksoy Institute of Oncology, Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Nilufer Guler Institute of Oncology, Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey

References

Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–93
PubMed Web of Science ®Google Scholar
Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer 2001; 92: 1759–68
PubMed Web of Science ®Google Scholar
Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, et al. Multicentre, Phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536–42
PubMed Web of Science ®Google Scholar
Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227–33
PubMed Web of Science ®Google Scholar
Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004; 43: 186–9
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date